希望医药开始第三期试验非激素内膜异位症治疗. Hope Medicine begins Phase III trial for non-hormonal endometriosis treatment.

霍普医药已在第三期临床试验中为第一个患者注射HMI-115, 这是一种治疗子宫内膜异位症的非激素疗法. Hope Medicine has dosed the first patient in a Phase III clinical trial for HMI-115, a non-hormonal therapy for endometriosis. 这项研究是随机的,双盲和安慰剂对照. The study is randomized, double-blind, and placebo-controlled. 治疗获得FDA快速跟踪和NMPA突破性疗法指标,其结果是II期阳性的,显示疼痛减轻而没有激素副作用. The treatment received FDA Fast Track and NMPA Breakthrough Therapy designations following positive Phase II results showing pain reduction without hormonal side effects.